Clinical Trial Update: Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial examining docetaxel and trastuzumab with or without carboplatin in HER2-positive breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED